Ertugliflozin (BioDeep_00000784438)
代谢物信息卡片
Ertugliflozin
化学式: C22H25ClO7 (436.128873)
中文名称: 埃格列净
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl
InChI: InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:188719
- KEGGdrug: D10313
- PubChem: 44814423
- DrugBank: DB11827
- ChEMBL: CHEMBL1770248
- CAS: 1210344-57-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Vaishali Sahasrabudhe, Kyle Matschke, Haihong Shi, Anne Hickman, Angela Kong, Barbara Rodríguez Spong, Beverly Nickerson, Kapildev K Arora. Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form.
International journal of clinical pharmacology and therapeutics.
2022 Jul; 60(7):317-326. doi:
10.5414/cp204212. [PMID: 35575420] - David Z I Cherney, Francesco Cosentino, Richard E Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Chih-Chin Liu, Christopher P Cannon. The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
Diabetes, obesity & metabolism.
2022 06; 24(6):1114-1122. doi:
10.1111/dom.14677. [PMID: 35233908] - Fudan Zhang, Wenting Wang, Xu Hou. Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta-analysis of data from randomized controlled trials.
Journal of diabetes investigation.
2022 Mar; 13(3):478-488. doi:
10.1111/jdi.13688. [PMID: 34610204] - Vasilios G Athyros, Chrysoula Boutari, Asterios Karagiannis. Ertugliflozin + metformin as a treatment option for type 2 diabetes.
Expert opinion on pharmacotherapy.
2021 Nov; 22(16):2105-2111. doi:
10.1080/14656566.2021.1939676. [PMID: 34130582] - Samuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, Darren K McGuire, Francesco Cosentino, Weichung J Shih, Jie Liu, Robert Frederich, James P Mancuso, Annaswamy Raji, Ira Gantz. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
BMJ open diabetes research & care.
2021 10; 9(1):. doi:
10.1136/bmjdrc-2021-002484. [PMID: 34620621] - David Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Robert Frederich, Mario Maldonado, Chih-Chin Liu, Jie Liu, Annpey Pong, Christopher P Cannon. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
Clinical journal of the American Society of Nephrology : CJASN.
2021 09; 16(9):1345-1354. doi:
10.2215/cjn.01130121. [PMID: 34497110] - Jean-Claude Marshall, Yali Liang, Vaishali Sahasrabudhe, Thomas Tensfeldt, Daryl J Fediuk, Susan Zhou, Rajesh Krishna, Vikas Kumar Dawra, Linda S Wood, Kevin Sweeney. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.
Journal of clinical pharmacology.
2021 09; 61(9):1220-1231. doi:
10.1002/jcph.1866. [PMID: 33813736] - Ildiko Lingvay, Michelle Greenberg, Silvina Gallo, Harry Shi, Jie Liu, Ira Gantz. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Diabetes, obesity & metabolism.
2021 07; 23(7):1640-1651. doi:
10.1111/dom.14385. [PMID: 33769675] - Daryl J Fediuk, Susan Zhou, Vikas Kumar Dawra, Vaishali Sahasrabudhe, Kevin Sweeney. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Clinical pharmacology in drug development.
2021 07; 10(7):696-706. doi:
10.1002/cpdd.885. [PMID: 33205593] - Yinhua Li, Gianluca Nucci, Yuichi Yamamoto, Daryl J Fediuk, Vaishali Sahasrabudhe. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.
Clinical pharmacology in drug development.
2021 07; 10(7):765-776. doi:
10.1002/cpdd.908. [PMID: 33434408] - David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong, Christopher P Cannon. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Diabetologia.
2021 06; 64(6):1256-1267. doi:
10.1007/s00125-021-05407-5. [PMID: 33665685] - Vikas Kumar Dawra, Kathleen Pelletier, Kyle Matschke, Haihong Shi, Anne Hickman, Susan Zhou, Rajesh Krishna, Vaishali Sahasrabudhe. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
Clinical pharmacology in drug development.
2021 05; 10(5):510-520. doi:
10.1002/cpdd.884. [PMID: 33135865] - Scott Culver Thomson, Volker Vallon. Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats.
American journal of physiology. Renal physiology.
2021 05; 320(5):F761-F771. doi:
10.1152/ajprenal.00552.2020. [PMID: 33645318] - Patrick R Lawler, Hongyan Liu, Claudia Frankfurter, Leif Erik Lovblom, Yuliya Lytvyn, Dylan Burger, Kevin D Burns, Davor Brinc, David Z I Cherney. Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Diabetes care.
2021 03; 44(3):e45-e47. doi:
10.2337/dc20-2265. [PMID: 33436398] - David Z I Cherney, Darren K McGuire, Bernard Charbonnel, Francesco Cosentino, Richard Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Chih-Chin Liu, Christopher P Cannon. Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.
Circulation.
2021 02; 143(6):602-605. doi:
10.1161/circulationaha.120.051901. [PMID: 33186063] - Ernesto Callegari, Jian Lin, Susanna Tse, Theunis C Goosen, Vaishali Sahasrabudhe. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
CPT: pharmacometrics & systems pharmacology.
2021 02; 10(2):127-136. doi:
10.1002/psp4.12581. [PMID: 33314761] - Richard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, Shrita Patel, Anne Hickman, Jie Liu, Lisa Tarasenko, Annpey Pong, Misoo C Ellison, Susan Huyck, Ira Gantz, Steven G Terra. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Diabetes, obesity & metabolism.
2020 12; 22(12):2276-2286. doi:
10.1111/dom.14150. [PMID: 32700421] - Silvina Gallo, Annaswamy Raji, Roberto A Calle, Annpey Pong, Christian Meyer. The effects of ertugliflozin on β-cell function: Pooled analysis from four phase 3 randomized controlled studies.
Diabetes, obesity & metabolism.
2020 12; 22(12):2267-2275. doi:
10.1111/dom.14149. [PMID: 32700393] - Daryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, David L Cutler, Neeta B Amin, Steven G Terra, Rebecca A Boyd, Rajesh Krishna, Vaishali Sahasrabudhe. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Clinical pharmacokinetics.
2020 08; 59(8):949-965. doi:
10.1007/s40262-020-00875-1. [PMID: 32337660] - David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Zhi J Xu, Shrita Patel, Anne Hickman, James P Mancuso, Ira Gantz, Steven G Terra. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
Diabetologia.
2020 06; 63(6):1128-1140. doi:
10.1007/s00125-020-05133-4. [PMID: 32236732] - Jie Liu, Shrita Patel, Nilo B Cater, Larry Wu, Susan Huyck, Steven G Terra, Anne Hickman, Amanda Darekar, Annpey Pong, Ira Gantz. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism.
2020 04; 22(4):574-582. doi:
10.1111/dom.13931. [PMID: 31797522] - Steven B Heymsfield, Annaswamy Raji, Silvina Gallo, Jie Liu, Annpey Pong, Hakima Hannachi, Steven G Terra. Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
Obesity (Silver Spring, Md.).
2020 04; 28(4):724-732. doi:
10.1002/oby.22748. [PMID: 32202075] - Vikas Kumar Dawra, Yali Liang, Hua Wei, Kathleen Pelletier, Haihong Shi, Anne Hickman, Almasa Bass, Steven G Terra, Susan Zhou, Rajesh Krishna, Vaishali Sahasrabudhe. Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Clinical pharmacology in drug development.
2020 01; 9(1):50-61. doi:
10.1002/cpdd.703. [PMID: 31207178] - Yinhua Li, Yuting Mu, Haihong Shi, Yali Liang, Zeyuan Liu, Kyle Matschke, Anne Hickman, Rajesh Krishna, Vaishali Sahasrabudhe. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
Clinical pharmacology in drug development.
2020 01; 9(1):97-106. doi:
10.1002/cpdd.686. [PMID: 30934166] - Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad, M Shahar Yar. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
European journal of medicinal chemistry.
2019 Dec; 184(?):111773. doi:
10.1016/j.ejmech.2019.111773. [PMID: 31630053] - Daryl J Fediuk, Kyle Matschke, Yali Liang, Kathleen B Pelletier, Hua Wei, Haihong Shi, Almasa Bass, Anne Hickman, Steven G Terra, Susan Zhou, Rajesh Krishna, Vaishali Sahasrabudhe. Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Clinical pharmacology in drug development.
2019 10; 8(7):884-894. doi:
10.1002/cpdd.722. [PMID: 31219248] - Wenjing Wang, Na Gan, Qiaomei Sun, Di Wu, Ruixue Gan, Man Zhang, Peixiao Tang, Hui Li. Study on the interaction of ertugliflozin with human serum albumin in vitro by multispectroscopic methods, molecular docking, and molecular dynamics simulation.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2019 Aug; 219(?):83-90. doi:
10.1016/j.saa.2019.04.047. [PMID: 31030051] - Dong-Gyun Han, Hwayoung Yun, In-Soo Yoon. A novel high-performance liquid chromatographic method combined with fluorescence detection for determination of ertugliflozin in rat plasma: Assessment of pharmacokinetic drug interaction potential of ertugliflozin with mefenamic acid and ketoconazole.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Aug; 1122-1123(?):49-57. doi:
10.1016/j.jchromb.2019.05.023. [PMID: 31153131] - Linong Ji, Yanmei Liu, Heng Miao, Yongli Xie, Ming Yang, Wei Wang, Yuting Mu, Ping Yan, Sharon Pan, Brett Lauring, Shu Liu, Susan Huyck, Yanping Qiu, Steven G Terra. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Diabetes, obesity & metabolism.
2019 06; 21(6):1474-1482. doi:
10.1111/dom.13681. [PMID: 30830724] - Vikas Kumar Dawra, David L Cutler, Susan Zhou, Rajesh Krishna, Haihong Shi, Yali Liang, Christine Alvey, Anne Hickman, Didier Saur, Steven G Terra, Vaishali Sahasrabudhe. Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
Clinical pharmacology in drug development.
2019 04; 8(3):314-325. doi:
10.1002/cpdd.472. [PMID: 29786959] - Vikas Kumar Dawra, Yali Liang, Haihong Shi, Almasa Bass, Anne Hickman, Steven G Terra, Susan Zhou, David Cutler, Vaishali Sahasrabudhe. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
International journal of clinical pharmacology and therapeutics.
2019 Apr; 57(4):207-216. doi:
10.5414/cp203343. [PMID: 30802200] - Silvina Gallo, Bernard Charbonnel, Allison Goldman, Harry Shi, Susan Huyck, Amanda Darekar, Brett Lauring, Steven G Terra. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Diabetes, obesity & metabolism.
2019 04; 21(4):1027-1036. doi:
10.1111/dom.13631. [PMID: 30614616] - Xiangjun Qiu, Saili Xie, Lei Ye, Ren-Ai Xu. UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma.
Analytical biochemistry.
2019 02; 567(?):112-116. doi:
10.1016/j.ab.2018.12.016. [PMID: 30578763] - Christopher P Cannon, Darren K McGuire, Richard Pratley, Sam Dagogo-Jack, James Mancuso, Susan Huyck, Bernard Charbonnel, Weichung J Shih, Silvina Gallo, Urszula Masiukiewicz, Gregory Golm, Francesco Cosentino, Brett Lauring, Steven G Terra. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
American heart journal.
2018 12; 206(?):11-23. doi:
10.1016/j.ahj.2018.08.016. [PMID: 30290289] - Vaishali Sahasrabudhe, Steven G Terra, Anne Hickman, Didier Saur, Sangeeta Raje, Haihong Shi, Kyle Matschke, Susan Zhou, David L Cutler. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Clinical therapeutics.
2018 10; 40(10):1701-1710. doi:
10.1016/j.clinthera.2018.06.015. [PMID: 30224193] - Vikas K Dawra, Vaishali Sahasrabudhe, Yali Liang, Kyle Matschke, Haihong Shi, Anne Hickman, Didier Saur, Steven G Terra, David L Cutler. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Clinical therapeutics.
2018 09; 40(9):1538-1547. doi:
10.1016/j.clinthera.2018.07.014. [PMID: 30170758] - Junyi Yang. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
Expert review of clinical pharmacology.
2018 Aug; 11(8):747-753. doi:
10.1080/17512433.2018.1503051. [PMID: 30025475] - Paula Nogueira da Silva, Raissa Alves da Conceição, Rodolfo do Couto Maia, Maria Leticia de Castro Barbosa. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
MedChemComm.
2018 Aug; 9(8):1273-1281. doi:
10.1039/c8md00183a. [PMID: 30151080] - Sangeeta Raje, Ernesto Callegari, Vaishali Sahasrabudhe, Alfin Vaz, Haihong Shi, Eric Fluhler, Eric J Woolf, Klaas Schildknegt, Kyle Matschke, Christine Alvey, Susan Zhou, Dimitris Papadopoulos, Robert Fountaine, Didier Saur, Steven G Terra, Lloyd Stevens, Daniel Gaunt, David L Cutler. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
Clinical and translational science.
2018 07; 11(4):405-411. doi:
10.1111/cts.12549. [PMID: 29575530] - Ronnie Aronson, Juan Frias, Allison Goldman, Amanda Darekar, Brett Lauring, Steven G Terra. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Diabetes, obesity & metabolism.
2018 06; 20(6):1453-1460. doi:
10.1111/dom.13251. [PMID: 29419917] - Richard E Pratley, Roy Eldor, Annaswamy Raji, Gregory Golm, Susan B Huyck, Yanping Qiu, Sheila Sunga, Jeremy Johnson, Steven G Terra, James P Mancuso, Samuel S Engel, Brett Lauring. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Diabetes, obesity & metabolism.
2018 05; 20(5):1111-1120. doi:
10.1111/dom.13194. [PMID: 29266675] - Samuel Dagogo-Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Darcy Hille, Yuqin Liao, Susan Huyck, Gregory Golm, Steven G Terra, James P Mancuso, Samuel S Engel, Brett Lauring. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Diabetes, obesity & metabolism.
2018 03; 20(3):530-540. doi:
10.1111/dom.13116. [PMID: 28921862] - Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring, Steven G Terra. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Diabetes, obesity & metabolism.
2018 03; 20(3):520-529. doi:
10.1111/dom.13103. [PMID: 28857451] - V Sahasrabudhe, S G Terra, A Hickman, D Saur, H Shi, M O'Gorman, Z Zhou, D L Cutler. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
Journal of clinical pharmacology.
2017 Nov; 57(11):1432-1443. doi:
10.1002/jcph.955. [PMID: 28703316] - Yao Li, Zongjun Shi, Lei Chen, Suxin Zheng, Sheng Li, Bo Xu, Zhenhong Liu, Jianyu Liu, Chongyang Deng, Fei Ye. Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
Journal of medicinal chemistry.
2017 05; 60(10):4173-4184. doi:
10.1021/acs.jmedchem.6b01818. [PMID: 28447791] - William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
Journal of the American Heart Association.
2017 May; 6(5):. doi:
10.1161/jaha.117.005686. [PMID: 28522675] - Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring, Sam Dagogo-Jack. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Diabetes, obesity & metabolism.
2017 05; 19(5):721-728. doi:
10.1111/dom.12888. [PMID: 28116776] - N B Amin, X Wang, J R Mitchell, D S Lee, G Nucci, J M Rusnak. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.
Diabetes, obesity & metabolism.
2015 Aug; 17(8):805-8. doi:
10.1111/dom.12486. [PMID: 25951755] - N B Amin, X Wang, S M Jain, D S Lee, G Nucci, J M Rusnak. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Diabetes, obesity & metabolism.
2015 Jun; 17(6):591-598. doi:
10.1111/dom.12460. [PMID: 25754396] - Meiyan Jiang, Peter S Steyger. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus.
Expert opinion on therapeutic patents.
2015; 25(11):1349-52. doi:
10.1517/13543776.2015.1076392. [PMID: 26291462] - Zhuang Miao, Gianluca Nucci, Neeta Amin, Raman Sharma, Vincent Mascitti, Meera Tugnait, Alfin D Vaz, Ernesto Callegari, Amit S Kalgutkar. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
Drug metabolism and disposition: the biological fate of chemicals.
2013 Feb; 41(2):445-56. doi:
10.1124/dmd.112.049551. [PMID: 23169609] - Amit S Kalgutkar, Meera Tugnait, Tong Zhu, Emi Kimoto, Zhuang Miao, Vincent Mascitti, Xin Yang, Beijing Tan, Robert L Walsky, Jonathan Chupka, Bo Feng, Ralph P Robinson. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Sep; 39(9):1609-19. doi:
10.1124/dmd.111.040675. [PMID: 21690265] - Sunil Nair, John P H Wilding. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.
The Journal of clinical endocrinology and metabolism.
2010 Jan; 95(1):34-42. doi:
10.1210/jc.2009-0473. [PMID: 19892839] - Harold Bays. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.
Current medical research and opinion.
2009 Mar; 25(3):671-81. doi:
10.1185/03007990802710422. [PMID: 19232040] - Muhammad A Abdul-Ghani, Ralph A DeFronzo. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2008 Sep; 14(6):782-90. doi:
10.4158/ep.14.6.782. [PMID: 18996802]